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Abstract	Opioid use, abuse, and associated mortality have reached an epidemic level. In some states, cannabis
is being used to treat chronic pain. To examine the hypothesis that medical marijuana legislation
may reduce adverse opioid-related outcomes if patients substitute cannabis for opioids for pain
management, we conducted a clinical inquiry (Clin-IQ). We searched Ovid MEDLINE, Ovid MEDLINE
In-Process, and Embase for studies using the search terms marijuana, cannabis, legal, marijuana
smoking, medical marijuana, opioid-related disorders, cannabis use, medical cannabis, legal aspect,
and opiate addiction. We included population-based articles published from January 1, 2012, through
December 5, 2018, that assessed the relationship between marijuana use and decriminalization and
the aforementioned opioid-related outcomes. Ten peer-reviewed studies met the inclusion criteria;
3 cross-sectional studies, 6 ecologic studies (ie, using aggregate data), and 1 retrospective cohort
study. Eight studies reported associations between policies decriminalizing marijuana and reduced
prescription opioid use, 1 study was inconclusive, and the retrospective cohort study reported an
increase in adverse opioid-related outcomes. These results should be interpreted with caution given
limitations associated with the studies’ design. Results demonstrating association between marijuana
decriminalization and opioid-related outcomes are mixed. Longitudinal studies are needed, and further
analysis of this policy should continue to be tracked. (J Patient Cent Res Rev. 2019;6:267-273.)
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Clinical Question
Is there less opioid abuse in states where marijuana
use has been decriminalized, either for medicinal or
recreational use?
Brief Answer
Yes. However, the evidence is mixed. While most
reviewed studies showed reductions in rates of opioid
overdose and opioid-related hospitalizations, among
other outcomes, in states with medical marijuana
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laws, a patient-level report and National Institute
on Drug Abuse data indicated an increase in opioid
use among cannabis users and higher rates of opioidrelated deaths in these states. Given these mixed
results, robust prospective studies are needed to
determine the impact of marijuana legislation on
opioid use and abuse.
Level of Evidence: B
Literature Search
Databases: Ovid MEDLINE, Ovid MEDLINE InProcess, PubMed, Embase.
Date range of literature search: January 1, 2012,
through December 5, 2018.
www.aurora.org/jpcrr
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Exclusion criteria: Animal studies, injectable drugs,
cannabidiol, non-English language.
Inclusion criteria: Date range within 2012–2018.
Search terms: Marijuana, cannabis, legal, marijuana
smoking, medical marijuana, opioid-related disorders,
cannabis use, medical cannabis, legal aspect, opiate
addiction.
Background
An estimated 25 million adults in the United States
suffer from daily pain, and another 23 million have
severe, recurrent pain. Persistent pain causes disability,
loss of productivity, lower quality of life, and overall
poor health.1 There has been a steady increase in the
number of opioid prescriptions in the past few decades
to manage pain. It is now estimated that the number
of annual prescriptions for opioids is approximately
equal to the number of adults in the country.2,3 Rates
of adverse effects of opiate medications, the primary
concerns being addiction and overdose,4 have
concomitantly increased with prescription opioid use.
As a result, an average of 115 individuals die daily in
the United States from opioid overdose.5
Patients who abuse or are dependent on prescription
opioids are 40 times more likely to use or abuse heroin
compared to those who take opioids as prescribed
and have no dependency issues. It is estimated that
4% of prescription opioid users are expected to
become heroin users.6 While the hypothesis that
marijuana may substitute for opioids exists, there is a
concurrent hypothesis that opioid and marijuana use
are not mutually exclusive and may be co-occurring.
For example, an increase in opioid use/abuse may
be associated with an increase in marijuana use. One
study reported co-occurring marijuana use to be 13.2%
among nonopioid users, 18.3% among prescription
opioid users, 40.1% among prescription opioid
misusers, 39.9% among those with prescription opioid
use disorder, and 58% among heroin users.7
In response to the opioid crisis, the U.S. Food and Drug
Administration (FDA), among other medical and public
health organizations, has attempted to identify strategies
to curb this epidemic. Marijuana is reported to be an
effective method to relieve pain,8,9 and authors of a
systematic review of the literature concluded that there
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are data, though limited, suggesting an association
between medical cannabis and a reduction in mortality
associated with prescription opioid use.10 As of 2015
(the cutoff year for data used in the analyses of this
study), there were 23 states that had legalized medical
marijuana. As of 2016, 31 states had legalized medical
marijuana; among these 31, 8 states plus Washington,
DC, also had legalized recreational marijuana.11
Almost two decades after the initiation of individual
state-led legalization of medical marijuana, there is
mixed evidence regarding the impact of marijuana on
opioid-related mortality rates. To that end, the objective
of this clinical inquiry (Clin-IQ) project is to explore
if a state’s decriminalization of marijuana, whether
medical or recreational, can attenuate the opioid crisis.
Methods
We searched Ovid MEDLINE, Ovid MEDLINE InProcess, PubMed, and Embase using the search terms
marijuana, cannabis, legal, marijuana smoking, medical
marijuana, opioid-related disorders, cannabis use,
medical cannabis, legal aspect, and opiate addiction.
Studies of animals, injectable drugs, and cannabidiol
(commonly referred to as CBD) were excluded. We
included articles published from January 1, 2012,
through December 5, 2018; however, we limited
marijuana-related data to 2015 or prior and opioidrelated data to 2016 or prior to allow a minimum of
1 year to elapse between marijuana decriminalization
and subsequent measures of opioid use. Surveillance
data for opioid use were not complete for years 2017
and beyond at the time this study was conducted.
Summary of Evidence
Table 1 summarizes the reviewed literature, which
included 1 retrospective cohort study, 3 cross-sectional
studies, and 6 ecologic studies using aggregate data.
The retrospective cohort study accessed data from
the National Epidemiological Survey on Alcohol
and Related Conditions, which assessed associations
between cannabis use and 1) prevalent opioid use, 2)
incident opioid use, and 3) prescription opioid use
disorder.12 This data set included a measure of patients’
chronic pain. Investigators reported that cannabis use
was associated with greater opioid use as defined by
these outcomes.12
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Table 1. Summary of Studies Describing the Impact of Medical Marijuana Legislation on Opioid Abuse
Authors (Year)

Objective

Study Design Population, Data Collected Results, Conclusions

Bachuber et al
(2014)21

Determine association
between presence of state
medical cannabis laws and
opioid-analgesic-overdose
mortality

Ecologic

Annual state-level death
• Medical marijuana
certificate data from 1999 to
legalization associated with a
2010 comparing overdose24.8% decrease in state-level
related mortality with time of
opioid-overdose mortality
marijuana legalization
rates compared to states
without marijuana policies

Bradford and
Investigate how
Bradford (2016)16 implementation of statelevel marijuana laws
changes prescribing
patterns

Ecologic

All drugs covered under
Medicare Part D from 2010
to 2013

• Average 1826 fewer daily
doses of prescriptions for pain
among states where medical
marijuana is decriminalized
compared to states where
marijuana is illegal (P<0.01)

Bradford and
Investigate association
Bradford (2017)17 between state-level
marijuana laws and
prescription drug spending

Ecologic

Average number of opioid
prescriptions filled by
Medicaid beneficiaries
during 2007–2014

• Approximately $1.01 billion
savings in 2014 if every
state had medical marijuana
legislation

Corroon et al
(2017)14

Survey marijuana users
to determine intentional
substitution of cannabis for
prescription drugs

Crosssectional

2774 self-selected marijuana • Cannabis as substitute for
users largely from U.S.,
prescription drugs, including
Canada, Europe
opioids

Liang et al
(2018)18

Examine if statewide
policies were associated
with a reduction in opioids
received by Medicaid
enrollees

Ecologic

Olfson et al
(2018)12

Determine association
between cannabis use and
change in risk of incident
nonmedical prescription
opioid use

Retrospective 34,653 participants in waves • Increase odds (odds ratio:
cohort
1 and 2 of the National
2.8) of incident nonmedical
Epidemiologic Survey
opioid among cannabis users
on Alcohol and Related
• Similar results when controlling
Conditions
for self-reported pain

Piper et al
(2017)15

Study the potential
Crosssubstitution effect of medical sectional
marijuana for opioids

• No influence by state
marijuana legislation
Prescription medication
data for patients enrolled
in fee-for-service Medicaid
programs

Online survey (n=1513) of
members of dispensaries
from Maine, Vermont,
Rhode Island

• Schedule II opioids (eg,
hydrocodone, oxycodone
[95% of all prescription
opioids]) were not associated,
but Schedule III opioids (eg,
codeine) were associated with
medical cannabis legalization

• Identified that 76.7% of opioid
users substituted marijuana
for opioids to treat chronic pain
• Not designed to estimate impact
of state marijuana legislation

Powell et al
(2018)19

Assess impact of timing
of medical marijuana
legislation on opioid-related
mortality rates

Ecologic

State-reported opioid-related • States enacting medical
mortality rates stratified by
marijuana legislation reported
timing of enacting medical
deaths per 100,000 as:
marijuana legislation: <2010, ≥2010: 3.27; never: 4.05;
≥2010, or never
<2010: 4.55

Shi (2017)20

Examine associations
between state medical
marijuana policies and
hospitalizations related to
marijuana and opioids

Ecologic

Annual state-level
hospitalization data from
1997 to 2014 in 27 states

Wen et al
(2015)13

Examine effect of medical
marijuana legislation on
substance use outcomes in
10 states

Crosssectional

Data from NSDUH during
• No statistically significant
2004–2012; questions collect association was observed
self-reported use of marijuana, between marijuana use and
alcohol, prescription pain killers prescription pain killer use

• Medical marijuana legalization
was associated with 9.4%–
23.0% state-level decrease in
opioid-related hospitalizations
compared to states without
marijuana policies

NSDUH, National Survey on Drug Use and Health.
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The highest quality of the cross-sectional studies used
data collected from the National Survey on Drug Use and
Health, which is sponsored by the U.S. Substance Abuse
and Mental Health Services Administration.13 Selfreported marijuana use was compared to self-reported
use of prescription pain killers, from 2004 to 2012 in 10
states. No significant association was observed in either
adolescents (age 12–20 years) or adults (age 21+ years).13
The other two cross-sectional studies were based on
convenience samples and investigated cannabis use
as a substitution for opioids. Corroon et al surveyed
marijuana users (n=2774) residing in the United States,
Canada, Europe, and “other” via Facebook.14 About 60%
of those surveyed self-identified as medical marijuana
users. Among the 1248 who responded affirmatively
to the question, “Have you ever used cannabis as a
substitute for prescription drugs?” substitutions of
marijuana were most commonly made for narcotic
opioids (35.8%), anxiolytics/benzodiazepines (13.6%),
and antidepressants (12.7%). This study found a positive,
though not statistically significant, association between
substituting marijuana use for opioid use. The study
design limited the ability to determine either causation
or association.14 The study by Piper et al involved
medical marijuana users (n=1513) in Maine, Vermont,
and Rhode Island.15 Of respondents who reported
regular use of opioid pain medications (n=215), more
than three-quarters (76.7%) reported a reduction in
opioid use after starting medical marijuana, supporting
marijuana use as a substitution for pain medication. This
study was conducted only in states where marijuana
had been decriminalized; therefore, the impact of legal
marijuana use cannot be assessed in the absence of a
control group. In addition, multiple authors of this study
had previous or hold current employment in cannabis
dispensaries, presenting potential conflicts of interest.15
Both of these studies had limitations related to selection
bias, convenience sampling, and survey design.
A 2016 study by Bradford and Bradford used 2010–
2013 data of all prescription drugs covered under
Medicare Part D to investigate the effects of medical
marijuana laws on opioid-prescribing patterns.16 Data
included 9 medical conditions, including pain, that were
mentioned in at least 4 states’ medical marijuana laws
and have at least 1 FDA-approved drug for off-label use.
A bivariate analysis comparing “prescriptions filled in
a state” and year of marijuana legalization resulted in
270 JPCRR • Volume 6, Issue 4 • Fall 2019

1826 fewer daily doses for pain medication filled per
physician per year (P<0.01). To evaluate unobserved
characteristics of general differences in prescribing
behaviors between physicians in states with and those
without marijuana laws, these results were compared
with other drug categories for which marijuana has no
clinical benefit (blood thinners, antibiotics, etc), and
no difference was found. Primary weaknesses of this
study included the ecologic study design and sample
population consisting of only those ≥65 years of age and
enrolled in Medicare Part D.16 Bradford and Bradford
conducted a subsequent study of similar design using
Medicaid data and reported similar findings.17
Another study used state-level Medicaid data to
assess changes in prescription opioid use over time.18
Prescription opioids were stratified into Schedule
II (eg, hydrocodone and oxycodone) and Schedule
III opioids (eg, codeine). Variables indicating the
presence and time of enactment of statewide medical
cannabis laws were included in the statistical analysis.
The authors reported no association with decreased
use of Schedule II opioids but a significant reduction
in the use of Schedule III opioids in states that had
decriminalized medical marijuana. It should be noted
that Schedule II opioids account for approximately
95% of all prescription opioids; therefore, the overall
impact of these reported associations is limited.18
Powell et al employed a study design similar to that
of Bradford and Bradford but which stratified states
into categories based on the timing of adopting
medical marijuana laws.19 Using 2010 as a cutoff,
states enacting medical marijuana legislation before
2010 were considered early adopters and those in 2010
or after were late adopters. States that did not have
medical marijuana laws were never adopters. Primary
results were mixed; late adopters were found to have
the lowest opioid-related mortality rates, followed by
never adopters. Early adopter states were found to have
the highest opioid-related mortality rates.19
In a 2017 ecologic study, Shi applied linear time-series
regression analysis using State Inpatient Databases that
included information from 27 states that met the inclusion
criteria.20 This study tested associations between the
implementation of medical marijuana policies and rates
of hospitalizations from 1997 to 2014 for opioid abuse/
dependence, marijuana abuse/dependence, and opioidTopic Synopsis

related overdose. Results showed an increase in marijuana
and opioid-related hospitalizations in all 27 states by
300%, on average, during this time period. However,
implementing medical marijuana policies was associated
with reduction in hospitalization rates by 23% for opioid
dependence or abuse (P=0.008) and 13% for opioid pain
reliever overdose (P<0.05). Additional analyses with
lagged effects were conducted, and when assuming a 1-year
lag post-medical marijuana policy implementation, there
was a 9.4% reduction in hospitalization rates for opioid
dependence or abuse (P<0.05). However, no difference
was observed for marijuana-related hospitalizations.
Inconsistencies in data collection and coding practices
were limitations of this study.20
A 2014 ecologic study by Bachuber et al investigated the
association of medical marijuana and opioid-overdose
mortality in the United States using vital records.21
Applying time-series analysis, the authors compared
opioid-overdose mortality rates between all 13 states

that had medical marijuana laws effective prior to and
during 1999–2010 and those that did not have medical
marijuana policies. Results showed a 24.8% lower
mean annual opioid-overdose mortality rate (95% CI:
-37.5% to -9.5%; P=0.003) in states with the uptake of
marijuana laws compared to states without marijuana
laws. This association strengthened over time. The
primary weakness of this study is its ecologic/aggregate
study design precluding information about medical use
among fatal overdose decedents.21
To supplement the published literature, we accessed
data on the prevalence of opioid prescriptions per 100
population and opioid-related overdose mortality rates
per 100,000 population for 2016 from the National
Institutes of Health/National Institute on Drug Abuse.22,23
Tables 2 and 3 summarize these results for states where
medical marijuana had and had not been decriminalized
by 2015, respectively. The crude average prevalence of
opioid prescriptions is approximately 20 people per 100

Table 2. Among States Where Medical Marijuana Was Decriminalized by 2015, the State-Specific Years When
Marijuana Was Decriminalized for Medical and Recreational Use, Prevalence of Opioid Prescriptions in 2016,
and Opioid-Related Death Rate in 2016

State
Alaska
Arizona
California
Colorado
Connecticut
Delaware
Hawaii
Illinois
Maine
Maryland
Massachusetts
Michigan
Minnesota
Montana
Nevada
New Hampshire
New Jersey
New Mexico
New York
Oregon
Rhode Island
Vermont
Washington
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Year
Medical

Year
Recreational

Opioid
Prescriptions per
100 Population22

Opioid Death Rate
(per 100,000
Population)23

1998
2010
1996
2000
2012
2011
2000
2013
1999
2003
2012
2008
2014
2004
2000
2013
2009
2007
2014
1998
2007
2004
1998

2014
NA
2016
2012
NA
NA
NA
NA
2016
NA
2016
NA
NA
NA
2016
NA
NA
NA
NA
2014
NA
NA
2012

58.9
70.2
44.8
59.8
55.9
79.2
41.9
56.8
66.9
58.7
47.1
84.9
46.9
69.8
80.7
64.3
52.6
65.1
42.7
76.3
60.3
58.6
64.9

12.5
11.4
4.9
9.5
24.5
16.9
5.2
15.3
25.2
30
29.7
18.5
7.4
4.2
13.3
35.8
16
17.5
15.1
7.6
26.7
18.4
30
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Table 3. Among States Where Medical Marijuana

Was Illegal Through 2015, Prevalence of Opioid
Prescriptions and Opioid-Related Death Rate in 2016

State
Alabama
Arkansas
Florida
Georgia
Idaho
Indiana
Iowa
Kansas
Kentucky
Louisiana
Mississippi
Missouri
Nebraska
North Carolina
North Dakota
Ohio
Oklahoma
Pennsylvania
South Carolina
South Dakota
Tennessee
Texas
Utah
Virginia
West Virginia
Wisconsin
Wyoming

Opioid
Prescriptions per
100 Population22

Opioid Death Rate
(per 100,000
Population)23

121.0
114.6
66.6
77.8
77.6
83.9
64.0
76.9
97.2
98.1
105.6
80.4
62.8
82.5
47.8
75.3
97.9
69.5
89.4
54.8
107.5
57.6
70.4
63.4
96.0
62.2
71.1

7.5
5.9
14.4
8.8
7.4
12.6
6.2
5.1
23.6
7.7
6.2
15.9
2.4
15.4
7.6
32.9
11.6
18.5
13.1
5.0
18.1
4.9
16.4
13.5
43.4
15.8
8.7

higher among states where medical marijuana is illegal
(mean: 81.1 of 100; range: 47.8–121.0) than states
where medical marijuana has been decriminalized
(mean: 61.2 of 100; range: 41.9–84.9).22 No adjustment
was made for time between policy change and
measurement of opioid prescription prevalence or
opioid-related overdose mortality rate. In contrast, the
average death rate of opioid-related overdoses is 3.79
people per 100,000 higher among states where medical
marijuana has been decriminalized (mean: 17.2 of
100,000; range: 4.2–35.8) compared to states where
marijuana was illegal through 2015 (mean: 13.4 of
100,000; range: 2.4–43.4).23 These findings stem from
a crude analysis using ecologic/aggregate study design;
therefore, overall impact and interpretation is limited.

272 JPCRR • Volume 6, Issue 4 • Fall 2019

Given that state-level data are ecologic and the
person-level data are drawn from convenience
samples, these data serve to generate hypotheses
rather than establishing causal relationships. This field
is rapidly changing because of policy implications.
For example, clinical practice may have changed as
a result of the U.S. Centers for Disease Control and
Prevention guidance on the prescribing practices of
opioids.24 Using the Strength of Recommendation
Taxonomy (SORT) criteria by Ebell et al, the level
of evidence to support the hypothesis that opioid use
decreases among states where marijuana use has been
decriminalized is level B (“recommendation based
on inconsistent or limited-quality patient-oriented
evidence”).25 Additional epidemiologic studies at the
patient level (especially cohort studies) are needed
to better understand the impact decriminalizing
marijuana use has on opioid abuse.
Conclusions
With the ongoing opioid epidemic, it is critical to
scrutinize medical marijuana as a substitute for pain
medications in terms of its analgesic properties and
potential harm. Based on this literature review, there
is mixed evidence regarding the impact of marijuana
legislation and prescription opioid-related outcomes.
Eight studies provided evidence of reductions in the
rate of opioid overdose, opioid-related hospitalizations,
number of narcotic pain prescriptions written, and
patient-reported substitution of marijuana for opiates,
in states with medical marijuana laws. However, the
one patient-level study reported an actual increase
in opioid use among cannabis users. Data from the
National Institute on Drug Abuse also indicated
states with medical marijuana laws had higher rates
of opioid-related overdose deaths. In addition, the
variability across study design, measures of opioid
abuse, and measures of marijuana use in the reviewed
studies contributes to the challenges in identifying a
consistent pattern in the results.
Given these mixed results, more robust studies in
which patients are followed prospectively to measure
the association between cannabis use and opioidrelated outcomes are sorely needed to determine the
impact of marijuana legislation on opioid use and
abuse.
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Patient-Friendly Recap
• The opioid addiction epidemic has pushed
health care providers to seek out new means
of managing chronic pain.
• In states where legal to do so, marijuana is
likely to be increasingly prescribed in lieu of
opioids when attempting to treat patients with
chronic pain.
• After reviewing the available literature to date,
the authors concluded there is less overall
opioid abuse in states that have legalized
marijuana; however, some contradictory
data indicating opioid-related deaths may
increase in these same states suggests further
research is necessary.
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